Policy & Regulation
ISA Pharmaceuticals selects ISA106 COVID-19 immunotherapy for clinical trial
3 March 2021 -

Immunotherapy company ISA Pharmaceuticals BV said on Tuesday that it has completed pre-clinical work for the novel COVID-19 immunotherapy ISA106 and is planning a phase 1 dose finding study in healthy volunteers in the next few months.

The company added that ISA106 is an immunotherapy agent intended to treat patients with SARS-CoV2 infections and prevent progressive pneumonia and further complications, thereby avoiding admission to hospital and ICU. It is designed to elicit a robust T cell immune response specifically against SARS-CoV2, the virus that causes COVID-19. T cells are very effective at eradicating viruses.

According to the company, boosting the T cell response against SARS-CoV2 in an infected individual at the right time is expected to shorten the infection period and prevent serious disease. T cells generated by ISA106 target multiple viral proteins that include the new variants.

ISA106 uses the company's Synthetic Long Peptide (SLP) platform technology. The same technology is used for its lead asset ISA101b, which is currently in late stage clinical development for the treatment of human papilloma virus type 16 (HPV16) induced cancers.